Monday, December 04, 2023
name of Prensa Latina
Bandera inglesa
English Edition
name of Prensa Latina



Revumenib: Hopeful drug to fight leukemia

Washington, Mar 17 (Prensa Latina) Syndax Pharmaceuticals, Inc. on Friday announced it found data from the Phase 1 portion of the ongoing Phase 1/2 AUGMENT-101 trial of revumenib in patients with nucleophosmin mutant (mNPM1) and KMT2A-rearranged (KMT2Ar) relapsed/refractory (R/R) acute leukemia.

Revumenib “has showed anticancer effects and possible signs of resistance,” according to scientists at the University of Texas and the Dana Farber Cancer Institute.

This hopeful drug managed to total disappearance of cancerous signs in 30% of people in clinical trial.

Revumenib, used to fight off advanced or resistant acute myeloid leukemia, has reached some remission degree in 53% of patients and complete remission in 30%.

The clinical trial found “the inhibition of a menin protein by revumenib produced encouraging responses in advanced acute leukemias with KMT2A or mutant NPM1 rearrangements”.

Experts warned of the emergence of selective resistance to menin inhibition.

The specialists identified specific mutations in MEN1 gene (encoding menin), which can lead to revumenib treatment resistance by altering the drug binding site.

Acute leukemia is usually characterized by mutation of the nucleophosmin 1 (NPM1) gene or rearrangement of the mixed-lineage leukemia 1 (KMT2Ar) gene, both of which have been shown to contribute to cancer progression.


name of Prensa Latina

| Text SMS to 8100 with content PL
Receive 4 mesages x 25 cup

© 2016-2021 Prensa Latina
Latin American News Agency

Radio – Publications  – Videos – News by the minute.
All Rigts Reserved.

St. E No 454 , Vedado,  Habana, Cuba.
Phones: (+53) 7 838 3496, (+53) 7 838 3497, (+53) 7 838 3498, (+53) 7 838 3499
Prensa Latina © 2021 .

Web Site developed by IT Division  Prensa Latina.